Compare Novo Nordisk A/S (NVO) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Financial Select Sector SPDR Fund — how do they compare? Novo Nordisk A/S trades at $44.73 (market cap $200.69B), while Financial Select Sector SPDR Fund trades at $57.39. The key difference: Novo Nordisk A/S pays a 3.98% dividend while Financial Select Sector SPDR Fund pays none, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | XLF | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | — |
52-Week High | $63.98 | $58.55 |
52-Week Low | $35.29 | $47.80 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
XLF, the Financial Select Sector SPDR Fund, trades at $57.3, down 1.38% over 24 hours. The technical outlook is neutral overall, with bullish moving averages but neutral oscillators, and key support at $57. Recent news highlights consolidation amid shifting interest rate expectations and fund manager rotation into financials in Q2 2026. The ETF offers exposure to 76 large-cap U.S. financial firms with a low expense ratio of 0.08%.
The outlook for XLF is balanced. Potential upside exists from rising interest rates benefiting banks and institutional inflows, but risks include economic sensitivity and sector volatility. The neutral technical and sentiment signals suggest a wait-and-see approach, with the dividend providing modest income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
